Copyright
©The Author(s) 2022.
World J Nephrol. Mar 25, 2022; 11(2): 58-72
Published online Mar 25, 2022. doi: 10.5527/wjn.v11.i2.58
Published online Mar 25, 2022. doi: 10.5527/wjn.v11.i2.58
Table 3 Comparison of laboratory measurements between patients with different coronavirus disease 2019 outcomes
Variable | Survival status | Respiratory progression due to COVID-19 | |||||
Total (n = 32) | Survivors | Non-survivors | P value | No (n = 19) | Yes (n = 13) | P value | |
Median (IQR) | Median (IQR) | ||||||
Lymphocytes (k/μL) | |||||||
On admission | 0.9 (0.8-1.4) | 1 (0.8-1.4) | 0.6 (5.3-1.3) | NS | 1 (0.8-1.5) | 0.8 (0.5-1.3) | NS |
Highest value of 10 d | 1.4 (1-1.7) | 1.3 (1-1.7) | 2.5 (1.4-3.4) | NS | 1.4 (1.2-1.8) | 0.9 (0.5-1.5) | NS |
Increase (%) | 10.4 (-2.3-51.6) | 10.3 (-2.6-42.7) | 60.8 (6.8-365.1) | NS | 37.6 (5.4-83.2) | 6.8 (-9.4-10.6) | NS |
CRP (mg/L) | |||||||
On admission | 19.3 (9.6-47.7) | 17.2 (8.1-88.2) | 22 (19.3-41.8) | NS | 17.2 (8.1-41.2) | 32.8 (10.6-88.2) | NS |
Highest value of 10 d | 55.6 (15.5-111.5) | 55.2 (15.1-108) | 83.5 (31.9-220) | NS | 34.8 (10.6-79) | 92 (31.9-149) | NS |
Increase (%) | 61.6 (-8.2-312.6) | 54.3 (-0.9-308.8) | 426.3 (-36.3-435.3) | NS | 45 (-15.5-160.4) | 300.9 (0-513.2) | NS |
WBC (mg/L) | |||||||
On admission | 5.9 (4.7-7.9) | 5.9 (4.5-8) | 6.2 (5.3-7.7) | NS | 5.9 (4.8-7.7) | 5.9 (4.2-8.8) | NS |
Highest value of 10 d | 7 (5.4-10.4) | 7 (5.3-10) | 9.4 (8-10.8) | NS | 6.9 (5.3-9.4) | 8 (5.9-12.6) | NS |
Increase (%) | 16.9 (-2.5-73.2) | 15.4 (-2.9-44.5) | 88.1 (21.4-103.8) | NS | 15.4 (0-36.4) | 74.9 (-10.1-103.8) | NS |
Neutrophils (k/μL) | |||||||
On admission | 4 (2.8-5.8) | 4 (2.8-5.8) | 3.8 (3.7-4.4) | NS | 3.8 (2.5-4.7) | 4.9 (3.4-6.7) | NS |
Highest value of 10 d | 5.3 (3.2-7.3) | 4.8 (3.1-7.3) | 5.6 (5.5-7.3) | NS | 4.6 (2.7-5.6) | 6.8 (5.3-9.6) | < 0.05 |
Increase (%) | 19.7 (-1.8-82.9) | 16.7 (-1.8-73.3) | 47.6 (19.8-154.8) | NS | 18.7 (3.3-39.8) | 102.4 (-6.8-162.8) | NS |
NLR | |||||||
On admission | 4.4 (2.9-6.5) | 4.1 (2.9-6.4) | 5.6 (2.8-7.1) | NS | 3.7 (2.6-6) | 4.9 (4.1-8.2) | NS |
Highest value of 10 d | 5 (2.7-10.6) | 4.7 (2.7-10.2) | 10 (3.3-14.6) | NS | 3.3 (2-5.3) | 13.4 (7.7-26.3) | < 0.01 |
Increase (%) | 17.8 (-12.8-116.1) | 18.4 (-14-65.6) | 6.4 (3.9-263.6) | NS | 2.5 (-31.8-25.9) | 235.9 (18.4-394.4) | < 0.01 |
Albumin (g/dL) | |||||||
On admission | 3.8 (3.5-4.1) | 3.8 (3.5-4.1) | 3.9 (3.7-4) | NS | 3.8 (3.5-4.1) | 3.9 (3.5-4) | |
Lowest value of 10 d | 3.3 (2.9-3.7) | 3.5 (2.9-3.7) | 2.9 (2.7-3.1) | < 0.05 | 3.3 (2.8-3.7) | 3.2 (2.9-3.5) | NS |
Decrease (%) | 12.1 (3.6-20.5) | 10 (3.6-18.8) | 25.6 (16.2-26.7) | NS | 10 (3.6-18.8) | 17.1 (7.7-20.5) | NS |
Ferritin (ng/mL) | |||||||
On admission | 448 (241.5-911) | 459 (249-940) | 408 (224-745) | NS | 341 (202-940) | 745 (369-904) | NS |
Highest value of 10 d | 1018 (445.5-1507) | 1038 (428-1559) | 605 (520-666) | NS | 548 (295-1455) | 1102 (666-1837) | NS |
Increase (%) | 49.3 (24.5-129.5) | 54.8 (26.3-129.2) | 27.5 (-21.9-146.6) | NS | 30.2 (26.3.4-97.7) | 129.7 (12.4-197.3) | NS |
LDH (U/L) | |||||||
On admission | 216 (174-285) | 222 (175-276) | 207 (174-298) | NS | 216 (158-297) | 217.5 (193-232.5) | NS |
Highest value of 10 d | 227 (183-273) | 225.5 (183-256) | 313 (272-330) | < 0.05 | 224 (184-256) | 261 (177.5-321.5) | NS |
Increase (%) | 5.7 (-13.8-60.6) | 5.6 (-13.8-25.2) | 89.7 (5-95.7) | < 0.05 | 5.8 (-14.7-25.2) | 5 (-11.6-89.7) | NS |
Ddimers (ng/mL) | |||||||
On admission | 1325 (772-2841) | 1080 (772-21562349 | 3089 (1244-5205) | NS | 1080 (732-3136) | 1640 (996-2349) | NS |
Highest value of 10 d | 1861.5 (1215-3503) | 1624 (1073-2526) | 3503 (3447-5032) | <0.05 | 1624 (1259-3191) | 2526 (1073-4134) | NS |
Increase (%) | 13 (-1.6-61.2) | 7.3 (-1.6-41.2) | 82.6 (19.1-195.8) | NS | 18.5 (0-52) | 1.4 (-21.3-104.3) | NS |
Troponin | |||||||
On admission | 72.3 (33.6-99.6) | 72.9 (26.9-102) | 71.4 (53-86.7) | NS | 53 (25.8-84.4) | 86.7 (49.8-102) | NS |
Highest value of 10 d | 84.6 (46.7-116) | 84.4 (38.3-118) | 92.6 (62-114) | NS | 66.5 (29.4-108) | 103 (83.2-118) | NS |
Increase (%) | 17.7 (2-39.6) | 17.6 (1-45) | 29.7 (17.3-31.5) | NS | 17.6 (1-50.4) | 29.7 (2.9-34.1) | NS |
- Citation: Bacharaki D, Karagiannis M, Sardeli A, Giannakopoulos P, Tziolos NR, Zoi V, Piliouras N, Arkoudis NA, Oikonomopoulos N, Tzannis K, Kavatha D, Antoniadou A, Vlahakos D, Lionaki S. Clinical presentation and outcomes of chronic dialysis patients with COVID-19: A single center experience from Greece . World J Nephrol 2022; 11(2): 58-72
- URL: https://www.wjgnet.com/2220-6124/full/v11/i2/58.htm
- DOI: https://dx.doi.org/10.5527/wjn.v11.i2.58